Niki BioSolutions, Inc.
NIKIHealthcare|Biotechnology|US
$1.58
+0.08 (+5.33%)
DCF Value
$0.14
Tangible Book / Share
$187.59
Cash / Share
$46.97
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Recent Press Releases
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine
Oct 26, 2026 · GlobeNewsWire
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
Oct 23, 2026 · GlobeNewsWire
Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series
Oct 16, 2026 · GlobeNewsWire
Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
Oct 14, 2026 · GlobeNewsWire
Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
Sep 25, 2026 · GlobeNewsWire
Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics
Sep 14, 2026 · GlobeNewsWire
Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Sep 8, 2026 · GlobeNewsWire